BioCryst Pharmaceuticals BCRX Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| Collaborative and other revenues | $7.96M+3.2% | $7.71M+18.2% | $6.52M+10.9% | $5.88M-6.7% | $6.3M-21.7% | |
| ORLADEYO | $615.94M+2.3% | $601.84M+4.8% | $574.34M+8.0% | $531.59M+10.1% | $483.04M+10.4% | |
| Other revenues | $22.78M-21.5% | $29.02M+13.9% | $25.47M-1.7% | $25.92M+26.8% | $20.45M+56.7% | |
| Product sales, net | $630.77M+1.2% | $623.15M+5.0% | $593.3M+7.6% | $551.63M+11.0% | $497.18M+12.3% | |
| Total trade receivables by Product | ||||||
| ORLADEYO | $370.25M+3.3% | $358.45M+4.7% | $342.38M+5.2% | $325.39M+7.0% | $304.1M+12.6% | |
| Peramivir | $11.41M-6.7% | $12.23M+432% | $2.3M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does BioCryst Pharmaceuticals break its business down?
- BioCryst Pharmaceuticals (BCRX) reports total revenues by product across 5 parts — Collaborative and other revenues, License and other revenues, ORLADEYO, Other revenues and Product sales, net. Each is extracted from the segment footnotes and tracked over time.
- Where does BioCryst Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in BioCryst Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.